Oncology R&D: ROI and the New Expectations

Investment in cancer drug development is complex — while the science is highly innovative, and the pipeline is the largest of any therapeutic area, oncology drug development suffers the highest failure rate of any TA. This panel will explore how to improve the odds in cancer drug development in order to provide better value for drug developers and patients. Our diverse panel will address who is and who should be making the decisions, economic return, strategies to improve investment value, and the role of new stakeholders. This is sure to be a provocative discussion.


  • Steve Heller, Principal, OncStrat LLC


  • Walter Capone, Chief Operating Officer, The Multiple Myeloma Research Foundation
  • Jeanne Farrell, PhD, Business Development Director, Icahn School of Medicine at Mount Sinai
  • Debasish Roychowdhury, MD, President, Nirvan Consultants LLC
  • Mark J. Simon, Advisor, Torreya Partners LLC

Cancer Progress has an outstanding reputation as the premier annual oncology conference that affords a unique dialogue among 200+ key opinion leaders in the cancer field. Join us as we bring together these top cancer researchers, clinical investigators and senior executives from the pharmaceutical, biotechnology, payer, regulatory and investment arenas. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking combine to make this a highly impactful conference.

The quality of the speaking faculty is a major contributor to the popularity and value of this conference. This year, executives attending the conference will also meet Peter Bach, Anna Barker, Robert Coffin, David Curiel, Giulio Draetta, Joel Dudley, David Haslam, Philip Kantoff, Brian Leyland-Jones, Tak Mak, Minesh P. Mehta, H. Ian Robins, Neal Rosen and David Solit, among other prestigious scientists and clinicians..

Our Keynote Speakers
Keynote Address
Colin Goddard, PhD, Chairman & Chief Executive Officer, Coferon Incorporated

A Dialogue: Valuing Value in Oncology
Professor David Haslam, CBE, FRCGO, FRCP, FFPH, Chairman, NICE
Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center